Business Wire

MA-VALAMIS

24.9.2020 10:02:15 CEST | Business Wire | Press release

Share
Valamis’ Global Survey Reveals the State of Learning & Development in the Workplace 2020

Valamis , the global leader in digital learning technologies and workforce development, published results from the “Global Survey on the State of Learning & Development (L&D) in the Workplace Report ,” which includes over 3000 people across more than 20 industries were surveyed from entry-level to C-Suite executives in organizations from Finland, France, Germany, Netherlands, Sweden, the US, and the UK.

Valamis conducted its 2nd annual “Global Survey on the State of Learning & Development (L&D) in the Workplace Report”, collecting insight into the shifting global priorities, challenges, behaviors, attitudes, and technologies in use for corporate learning and development, with additional research into the impact of COVID-19.

The importance of learning & development in the workforce

Findings from the survey show that roughly 93% of respondents globally believe updating knowledge and skills are important to an organization’s success and more than 50% of executives and the C-Suite value skills development as extremely important to an organization’s future success. Although the importance of learning and development has been recognized in every country surveyed, over 74% of respondents believe their organizations are actively encouraging the workforce to develop their skills and nearly 56% of respondents had a dedicated person or team responsible for learning and development at their organization.

Time to learn

Despite the globally acknowledged importance of learning and development, for the second consecutive year conducting the survey, the biggest challenge plaguing learning and development within organizations is a lack of time or perceived time affluence with regards to learning. 48% of respondents globally denoted a lack of time as the biggest challenge for learning and development. Interestingly, survey participants at the executive and C-suite level note that they use their digital learning environment the most frequently (Nearly 30% using it every day) of all survey participants.

Tools in place for corporate learning

25% of respondents specify not having the right tools in place as one of the top three challenges for learning & development. Approximately 15% of respondents demarcate that their organization does not have a digital learning environment in place at their organization, and the Netherlands has the highest percentage of respondents of all the countries surveyed that specify they have a Learning Management System (LMS) (24%) or Learning Experience Platform (LXP or LEP) (20%) in place, whereas the United States (28%), United Kingdom (29%), and Germany (28%) have the highest percentages of respondents relying on online courses or Massive Open Online Courses (MOOCs). Finland has the highest number of respondents (18%) that suggest their organization has no digital learning tools in place.

COVID-19 & L&D

Approximately 70% of executives within the global survey express they value digital learning and development more as a result of COVID-19, and over 67% of all global participants in the survey believe digital learning and development can help minimize the effects of shocks and stresses of future events.

“2020 has been a challenging year for many organizations and individuals worldwide. Our global survey on the state of learning and development highlights an internationally growing acknowledgment from the C-suite that L&D is critical to the success of their organizations, and with the right tools in place organizations can adapt and reskill in the face of unforeseen events,” said Janne Hietala, Chief Visionary Officer, Valamis.

Download the report here .
*Please note the survey results are in English

About Valamis

Valamis is a digital learning company specializing in workforce development, and the developer of Valamis - Learning Experience Platform. Valamis' customers are large organizations spanning all industries—predominantly finance and insurance, complex manufacturing, and professional services. Headquartered in Joensuu, Finland, Valamis operates internationally with offices in the US, the UK, Germany, the Netherlands, Russia, and India.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye